WELL Health Announces Intention to Renew Normal Course Issuer Bid
VANCOUVER, BC, April 26, 2022 /CNW/ - WELL Health Technologies Corp. (TSX: WELL) (the "Company" or "WELL"), a company focused on positively impacting health outcomes by leveraging technology to empower practitioners and their patients globally, today announced that it has filed its Notice of Intention to Make a Normal Course Issuer Bid ("NCIB") with the Toronto Stock Exchange ("TSX").
The NCIB remains subject to approval by the TSX and would be a renewal of its current NCIB expiring May 11, 2022. The NCIB renewal has been approved by WELL's Board of Directors (the "Board"), but it is subject to acceptance by the TSX, and if accepted, will be made in accordance with the applicable rules and policies of the TSX and Canadian securities laws. The commencement and termination dates for this NCIB and confirmation of the exact number of Shares subject to the NCIB will be announced once the NCIB has been approved by the TSX.
WELL believes that purchases of its common shares (the "Shares") pursuant to the NCIB will contribute to the facilitation of an orderly market and be in the best interests of the Company and its shareholders. In the event that WELL believes that its Shares begin trading in a price range that does not adequately reflect their underlying value based on WELL's business prospects and financial position, WELL may purchase Shares pursuant to the NCIB. Depending upon future price movements and other factors, WELL believes that its outstanding Shares represent an attractive investment and a desirable use of a portion of its corporate funds.
At the opening of the stock market on today's date, the Company is expected to have 210,383,666 Shares issued and outstanding. Under the NCIB, if approved by the TSX, the Company may acquire up to 2.5% of the number of issued and outstanding Shares of the Company over the next 12-month period, or an aggregate of 5,259,591 Shares based on the current number of issued and outstanding Shares. The exact number of Shares that are subject to the NCIB will be determined on the date of acceptance of the NCIB.
Purchases subject to this NCIB will be made on the open market through the facilities of the TSX and any alternative trading systems in Canada by a broker on behalf of the Company in accordance with applicable regulatory requirements. All Shares purchased by the Company under the NCIB will be returned to treasury and cancelled.
The Company's current NCIB expires on May 11, 2022. The Board believes that the recent market prices of the Shares do not properly reflect the underlying value of such Shares. As a result, WELL recently purchased 50,000 Shares in the period following release of the Company's fourth quarter results on March 31, 2022, at an average price of $4.85 on the TSX pursuant to its current NCIB.
Per: "Hamed Shahbazi"
Hamed Shahbazi
Chief Executive Officer, Chairman and Director
WELL is a technology enabled healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and is part of the TSX Composite Index. To learn more about the Company, please visit: www.well.company.'
This news release contains "Forward-Looking Information" within the meaning of applicable Canadian securities laws, including, without limitation, the expectation that the TSX will approve the NCIB and that the Company will conduct the NCIB and its future purpose. Forward-Looking Information is based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. Forward-Looking Information generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-Looking Information involves known and unknown risks, uncertainties and other factors that may cause future results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those Forward-Looking Information and the Forward-Looking Information is not a guarantee of future performance. WELL's statements expressed or implied by the Forward-Looking Information is subject to a number of risks, uncertainties, and conditions, many of which are outside of WELL 's control, and undue reliance should not be placed on such statements. Forward-Looking Information is qualified in their entirety by inherent risks and uncertainties, including: direct and indirect material adverse effects from the COVID-19 pandemic; adverse market conditions; risks inherent in the primary healthcare sector in general; regulatory and legislative changes; that future results may vary from historical results; that market competition may affect the business, results and financial condition of WELL and other risk factors identified in documents filed by WELL under its profile at www.sedar.com, including its most recent Annual Information Form. Except as required by securities law, WELL does not assume any obligation to update or revise any Forward-Looking Information, whether as a result of new information, events or otherwise.
SOURCE WELL Health Technologies Corp.
Tyler Baba, Investor Relations, Manager, [email protected], 604-628-7266
Share this article